Abstract
Background: There is no prospective data to guide treatment strategies after progression on cyclin dependent kinases 4 and 6 inhibitors (CDK4/6i) in oestrogen receptor positive (ER+) metastatic breast cancer. Here we present a single-institution experience to assess prescribing patterns and outcomes with subsequent therapies post CDK4/6i progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
